Search results for "Highlights"
Tirzepatide may improve glycemic control when added to insulin glargine in type 2 diabetes
An industry-sponsored phase 3 trial found statistically significant improvements in HbA1c level among patients with type 2 diabetes who had inadequate glycemic control on insulin glargine and were randomly assigned to subcutaneous tirzepatide once weekly versus placebo.
https://diabetes.acponline.org/archives/2022/02/11/1.htm
11 Feb 2022
Metformin use during pregnancy not associated with adverse outcomes in children
A industry-conducted cohort study in Finland found that childhood obesity, hypoglycemia, hyperglycemia, diabetes, and challenges in motor-social development did not appear to be associated with in utero exposure to metformin or metformin and insulin versus insulin alone.
https://diabetes.acponline.org/archives/2022/01/14/3.htm
14 Jan 2022
Association of inflammation with mortality in COVID-19 didn't differ by diabetes status
A single-center, case-control study of patients who were hospitalized with COVID-19 found a link between elevated levels of IL-6, IL-8, and interferon-γ-induced protein 10 and mortality risk, regardless of whether patients had type 2 diabetes.
https://diabetes.acponline.org/archives/2022/01/14/2.htm
14 Jan 2022
Neurologists update guideline on treatment of painful diabetic neuropathy
The updated guideline from the American Academy of Neurology supports offering tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, gabapentinoids, and/or sodium channel blockers to reduce pain from diabetic neuropathy.
https://diabetes.acponline.org/archives/2022/01/14/1.htm
14 Jan 2022
Adults with diabetes more likely to report mental stress during the COVID-19 pandemic
An online survey of U.S. adults in mid-2020, most of whom were White women, found that those with diabetes were less likely to report resilience and more likely to experience depression than adults without diabetes.
https://diabetes.acponline.org/archives/2021/12/10/3.htm
10 Dec 2021
Study finds long-term reductions in cardiovascular risk factors with SGLT-2 inhibitors
While the meta-analysis also found durable reductions in macrovascular complications and mortality with sodium-glucose cotransporter-2 (SGLT-2) inhibitors versus placebo, there were insufficient data comparing the drug class to other antihyperglycemic medications.
https://diabetes.acponline.org/archives/2021/12/10/2.htm
10 Dec 2021
Hospitalizations for diabetes complications fell, were replaced by other causes
An analysis of excess hospitalizations among people with diabetes in England from 2003 to 2018 found that diabetes caused fewer of their hospital stays, with respiratory disease and cancer becoming more predominant diagnoses.
https://diabetes.acponline.org/archives/2021/12/10/1.htm
10 Dec 2021
Spotlight on dementia and glycemic control
Prediabetes and diabetes were associated with development of dementia in a South Korean study, and poorly controlled diabetes was tied to increased risk of incident cognitive impairment or progression to dementia in a Swedish study.
https://diabetes.acponline.org/archives/2021/11/12/5.htm
12 Nov 2021
No long-term disruption of glycemic control seen after COVID-19, study finds
The authors of a small Italian study of hospitalized COVID-19 patients speculated that reversible transient factors, such as inflammation-induced insulin resistance, may cause the hyperglycemia that occurs in some patients with and without diabetes during infection.
https://diabetes.acponline.org/archives/2021/11/12/2.htm
12 Nov 2021
Rates of hypoglycemic, hyperglycemic crises high in patients with diabetes and ESKD
The results of a retrospective study of U.S. data in patients with both diabetes and end-stage kidney disease (ESKD) indicate that current glycemic monitoring and treatment in this population are suboptimal, the authors said.
https://diabetes.acponline.org/archives/2021/11/12/3.htm
12 Nov 2021